Therapy for neurocysticercosis

References

• Bern C, Garcia HH, Evans C etal. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin. Infect. Dis. 29,1203–1209 (1999).
   PubMed Web of Science ®Google Scholar
• Centers for Diseases Control and Prevention. Recommendations of the International Task Force for Disease Eradication (ITFDE). MMWR 42 (16), 1–25 (1993).
   PubMedGoogle Scholar
• Roman G. La neurocisticercosis: una perspectiva de salud pliblica. Rev Newel 36,71–74 (2003).
   Google Scholar
• Roman G, Sotelo J, Del Brutto O et al. A proposal to declare neurocysticercosis an international reportable disease. Bull. World Health Organ. 78,399–406 (2000).
   PubMed Web of Science ®Google Scholar
• White AC Jr. Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis and management. Ann. Rev Med. 51, 187–206 (2000).
   PubMed Web of Science ®Google Scholar
• •Good overview of all aspects of neurocysticercosis.
   Google Scholar
• Takayanagui OM, Bettini MJCB, Takayanagui AM1\A et al Epidemiological surveillance of neurocysticercosis in Ribeirao Preto, SP, Brazil. Arq. Neuropsiquiatr 60\(Suppl. 1), 332 (2002).
   Google Scholar
• Escobar A. The pathology of neurocysticercosis. In: Cysticerrosis of the Central Nervous System. Palacios E, Rodriguez-Carbajal J, Taveras JM (Eds). Charles C Thomas, IL, USA, 27–54 (1983).
   Google Scholar
• Del Brutto OH, Sotelo J, Roman GC. Neurogsticerrosis. A Clinical Handbook Swets & Zeitlinger Publishers, Lisse, Holland (1998).
   Google Scholar
• •Excellent book which provides a good overview of all aspects of neurocysticercosis.
   Google Scholar
• Garcia IIf I, Del Brutto OH. Taenia so/iumcysticercosis. Infect. Dis. Clin. North Arn. 14,97–119 (2000).
   PubMedGoogle Scholar
• Sciutto E, Fragoso G, Fleury A et al. Taenia solium disease in humans and pigs: an ancient parasitosis disease rooted in developing countries and emerging as a major health problem of global dimensions. Nlicrebes Infect. 2,1875–1890 (2000).
   PubMed Web of Science ®Google Scholar
• Colli BO, Carlotti CG, Assirati JA Jr, Machado HR, Valenga M, Amato MCM. Surgical treatment of cerebral cysticercosis: long-term results and prognostic factors. Neurosurg. Focus 12 (6), 1–13 (2002).
   Google Scholar
• Pittella JE. Neurocysticercosis. Brain Pathol 7,681–693 (1997).
   PubMed Web of Science ®Google Scholar
• Sotelo J, Mann C. Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. Neurosurg. 66,686-689 (1987).
   Google Scholar
• Estaliol B, Corona T, Abad P A prognostic classification of cerebral cysticercosis: therapeutic implications. j Newel Neurosurg. P9rhiatry49, 1131–1134 (1986).
   Google Scholar
• Sotelo J, Del Brutto OH. Review of neurocysticercosis. Neurosurg. Focus 12(6)1,1–7 (2002).
   Google Scholar
• •Good review of all aspects of neurocysticercosis.
   Google Scholar
• Forlenza OV, Vieira Filho AHG, Nóbrega JPS et al. Psychiatric manifestations of neurocysticercosis: a study of 38 patients from a neurology clinic in Brazil. Neural Neurosurg. P9rhiatry62, 612–616 (1997).
   Google Scholar
• Hoberg ER Taenia tapeworms: their biology, evolution and socioeconomic significance. Maybes Infect. 4,859–866 (2002).
   PubMed Web of Science ®Google Scholar
• Machado LR, Livramento JA, Vaz AJ et al IgG intrathecal synthesis and specific antibody index in patients with neurocysticercosis. An7. Neuropsiquiatr 60,395–399 (2002).
   Google Scholar
• Proalio-Narvaez JV, Meza-Lucas A, Mata- Ruiz O, Garcia-Jeronimo RC, Correa D. Laboratory diagnosis of human neurocysticercosis: double-blind comparison of enzyme-linked immunosorbent assay and electroimmunotransfer blot assay. j Clin. Ma-able" 40,2115–2118 (2002).
   Google Scholar
• Gekeler F, Eichenlaub S, Mendoza EG, Sotelo J, Hoelscher M, Löscher T Sensitivity and specificity of ELISA and immunoblot for diagnosing neurocysticercosis. Eur. j din. Mcrobiel Infect. Dis. 21,227–229 (2002).
   PubMed Web of Science ®Google Scholar
• Greene RM, Hancock K, Wilkins PP, Tsang VCW. Taenia soliurd molecular cloning and serologic evaluation of 14-and 18-kDa related, diagnostic antigens. Parasite" 86,1001–1007 (2000).
   Google Scholar
• Plancarte A, Hirota C, Martinez-Ocalia J, Mendoza-Hernandez G, Centeno E, Risser A. Characterization of gp39-42 and gp24 antigens from Taenia soliumcysticerci and of their antigenic gp10 subunit. Parasite" Res 85,680–684 (1999).
   Google Scholar
• Del Brutto OH, Rajshekhar V, White AC Jr et al Proposed diagnostic criteria for neurocysticercosis. Neurology57, 177–183 (2001).
   PubMed Web of Science ®Google Scholar
• White AC Jr. Neurocysticercosis: a major cause of neurological disease worldwide. Clin. Infect. Dis. 24,101–115 (1997).
   PubMed Web of Science ®Google Scholar
• Garcia HH, Evans CAW, Nash TE et al Current consensus guidelines for treatment of neurocysticercosis. Clin. Mcrobiel Rev. 15,747–756 (2002).
   PubMed Web of Science ®Google Scholar
• •Consensus guidelines of therapy based on a panel of experts in neurocysticercosis.
   Google Scholar
• Sotelo J, Jung H. Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin. Pharmacokinet. 34,503–515 (1998).
   PubMed Web of Science ®Google Scholar
• ••Excellent review on the pharmacokineticsof praziquantel and albendazole.
   Google Scholar
• Pretell EJ, Garcia IIf I, Custodio N et al Short regimen of praziquantel in the treatment of single brain enhancing lesions. Clin. Neural Neurosurg. 102, 215–218 (2000).
   PubMed Web of Science ®Google Scholar
• Medina-Santillan R, Mateos-Garcia E, Reyes-Garcia G et al Analisis farmacoeconómino del esquema corto de praziquantel en el tratamiento de la neurocisticercosis. Gar. Med. Mex. 138, 203–207 (2002).
   PubMedGoogle Scholar
• Del Brutto OH, Campos X, Sanchez J, Mosquera A. Single-day praziquantel versus 1-week albendazole for neurocysticercosis. Neurology 52, 1079–1081 (1999).
   PubMed Web of Science ®Google Scholar
• Lopez-Gómez M, Castro N, Jung H, Sotelo J, Corona T Optimization of the single-day praziquantel therapy for neurocysticercosis. Neurology 57, 1929–1930 (2001).
   PubMed Web of Science ®Google Scholar
• Pretell EJ, Garcia HH, Gilman RII, Saavedra H, Martinez M. Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. Clin. Newel Neurosurg. 103,175–177 (2001).
   Google Scholar
• Garcia HH, Gilman RII, Horton J et al Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Neurology48,1421–1427 (1997).
   PubMed Web of Science ®Google Scholar
• Singhi P, Dayal D, Khandelwal N. One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double-blind trial. Pediatr Infect. Dis.j 22,268–272 (2003).
   Google Scholar
• Proaño JV, Madrazo I, Avelar F, Lopez-Felix B, Diaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl. I Med. 345,879–885 (2001).
   Google Scholar
• Takayanagui OM, Jardim E. Therapy for neurocysticercosis: comparison between albendazole and praziquantel. krh. Neural. 49, 290–294 (1992).
   Google Scholar
• Bang OY, Heo JH, Choi SA, Kim DI. Large cerebral infarction during praziquantel therapy in neurocysticercosis. Stroke 28, 211–213 (1997).
   PubMed Web of Science ®Google Scholar
• Takayanagui OM, Lanchote VL, Marques MPC, Bonato PS. Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther. Drug- Monit. 19, 51–55 (1997).
   PubMed Web of Science ®Google Scholar
• Agapejev S, Silva MD, Ueda AK. Severe forms of neurocysticercosis. Treatment with albendazole. kv. Neuropsiquiatr 54, 82–93 (1996).
   Google Scholar
• Riley T, White AC. Management of neurocysticercosis. CNS Drugs 17, 577–591 (2003).
   PubMed Web of Science ®Google Scholar
• Carpio A, Escobar A, Hauser WA. Cysticercosis and epilepsy: a critical review. Epilepsia 39, 1025–1040 (1998).
   PubMed Web of Science ®Google Scholar
• Carpio A, Hauser WA. Prognosis of seizure recurrence in patients with newly diagnosed neurocysticercosis. Neumlogy59, 1730–1734 (2002).
   PubMed Web of Science ®Google Scholar
• Nash TE. Human case management and treatment of cysticercosis. Acta Tropica 87, 61–69 (2003).
   PubMed Web of Science ®Google Scholar
• Leite JP, Terra-Bustamante VC, Fernandes RMF et al Calcified neurocysticercotic lesions and post-surgery seizure control in temporal lobe epilepsy. Neurology55, 1485–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Fleury A, Gomez T, Alvarez I et al High prevalence of calcified silent neurocysticercosis in a rural village of Mexico. Neumepidemiology22, 139–145 (2003).
   PubMed Web of Science ®Google Scholar
• Carpio A. Neurocysticercosis: an update. Lancet Infect. Dir. 2, 751–762 (2002).
   PubMedGoogle Scholar
• Salinas R, Prasad K. Drugs for treating neurocysticercosis (tapeworm infection of the brain). Cochrane Database Syst. Rev. Issue 2, CD000215 (2000).
   Google Scholar
• Salinas R, Counsell C, Prasad K, Gelband H, Garner P. Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. 7i-op. Med. Intern. Health 4, 713–718 (1999).
   Google Scholar
• Evans C, Garcia HH, Gilman RII, Friedland JS. Controversies in the management of cysticercosis. Emerg. Infect. Dis. 3, 403–405 (1997).
   PubMed Web of Science ®Google Scholar
• Del Brutto OH. Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients. J. Neural. Neurosurg. fiychiatry62, 659–661 (1997).
   Google Scholar
• Sotelo J, Hisser A. Neurocysticercosis: practical treatment guidelines. CNS Drugs 7, 17–25 (1997).
   Web of Science ®Google Scholar
• Proalio JV, Madrazo I, Garcia L, Garcia- Torres E, Correa D. Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle. J. Neurosurg. 87, 29–33 (1997).
   Google Scholar
• Marques MPC, Takayanagui OM, Bonato PS, Santos SRCJ, Lanchote VL. Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. Chimlityll, 218–223 (1999).
   Google Scholar
• Schipper HG, Koopmans RP, Nagy J, Butter JJ, Kager PA, van Boxtel CJ. Effect of dose increase or cimetidine coadministration on albendazole bioavailability. Am. J. Pop. Med. Hyg. 63, 270–273 (2000).
   Google Scholar
• Mirfazaelian A, Dadashzadeh S, Rouini MR. Effect of gender in the disposition of albendazole metabolites in humans. Eur. j Clin. Pharmacol 58, 403–408 (2002).
   PubMedGoogle Scholar
• Marques MP, Takayanagui OM, Lanchote VL. Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450. Braz. J. Med. Biol. Res. 35, 261–269 (2002).
   Google Scholar
• Castro N, Medina R, Sotelo J, Jung H. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob. Agents Chemother. 44, 2903–2904 (2000).
   PubMed Web of Science ®Google Scholar
• Castro N, Jung H, Medina R, Gonzalez- Esquivel D, Lopez M, Sotelo J. Interaction between grapefruit juice and praziquantel in humans. Antimiavb. Agents Chemother. 46, 1614–1616 (2002).
   Google Scholar
• Jung H, Medina R, Castro N, Corona T, Sotelo J. Pharmacokinetic study of praziquantel alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob. Agents Chemother. 41, 1256–1259 (1997).
   Google Scholar
• Lanchote VL, Garcia FS, Dreossi SA, Takayanagui OM. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. Ther. Drug-Monit. 24, 338–345 (2002).
   PubMed Web of Science ®Google Scholar
• ••First description of the pharmacologicalinteraction between albendazole and antiepileptic drugs.
   Google Scholar
• Lanchote VL, Marques MPC, Takayanagui OM, Carvalho R, Paias FO, Bonato PS. Simultaneous determination of albendazole sulfoxide enantiomers and albendazole sulfone in plasma. J. Chromatogr B. 709, 273–279 (1998).
   PubMed Web of Science ®Google Scholar
• Paias FO, Lanchote VL, Takayanagui OM, Bonato PS. Enantioselective analysis of albendazole sulfoxide in plasma using the chiral stationary phase. Chirality 9, 722–726 (1997).
   PubMed Web of Science ®Google Scholar
• Paias FO, Lanchote VL, Takayanagui OM, Bonato PS. Enantioselective analysis of albendazole sulfoxide in cerebrospinal fluid by capillary electrophoresis. Electrophoresis 22, 3263–3269 (2001).
   PubMed Web of Science ®Google Scholar
• Takayanagui OM, Bonato PS, Dreossi SAC, Lanchote VL. Enatioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. BE J. Gun. Pharmacol 54, 125–130 (2002).
   Web of Science ®Google Scholar
• Kearney BP, Aweeka FT The penetration of anti-infectives into the central nervous system. Neural. Clin. 17, 883–900 (1999).
   PubMed Web of Science ®Google Scholar
• Odashima NS. Enantiomea of albendazole sulfoxide in plasma and cembrospinal fluid: therapeutic efficacy in treatment of active neurocysticarosis. Thesis. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto-SP, Brazil, 1–64 (2003).
   Google Scholar
• Cioli D. Chemotherapy of schistosomiasis: an update. Parasital Today14, 418–422 (1998).
   PubMedGoogle Scholar
• Hisser A, Lightowlers MW. Vaccination against Taenia solium cysticercosis. Alem. Inst. Oswald° Cruz96, 353–356 (2001).
   PubMed Web of Science ®Google Scholar
• Wang Q, Sun S, Hu Z, Wu D, Wang Z. Immune response and protection elicited by DNA immunization against Taenia cysticercosis. Vaccine21, 1672–1680 (2003).
   Google Scholar
• Sotelo J. Neurocysticercosis. Eradication of cysticercosis is an attainable goal. BE Med. 1326, 511–512 (2003).
   Google Scholar
• Pan American Health Organization. Epidemiologia y control de la teniasisi cisticercosis en America Latina. Version 3.0 Organización Panarrxhicana de la Salucl (1994).
   Google Scholar
• Cruz M, Davis A, Dixon H, Pawlowski ZS, Proano J. Operational studies on the control of Taenia solium taeniasisi cysticercosis in Ecuador. Bull. World Health Chgan. 67, 401–407 (1989).
   PubMed Web of Science ®Google Scholar
• Sarti E, Hisser A, Schantz P et al Development and evaluation of a health education intervention against Taenia solium in a rural community in Mexico. Am. J. Trap. Med. Hyg. 56, 127–132 (1997).
   Google Scholar
• Engels D, Urbani C, Belotto A, Meslin F, Savioli L. The control of human (neuro)cysticercosis: which way forward? Acta Tropica 87, 177–182 (2003).
   Google Scholar
• Takayanagui OM, FebrOnio LHP, Bergamini AMM et al. Fiscalizagao de hortas produtoras de verduras no municipio de Ribeirao Preto, SR Rev. Soc. Bras. Med. 7i-op. 33, 169–174 (2000).
   Google Scholar
• Takayanagui OM, Oliveira CD, Bergamini AMM et al Fiscalizagao de verduras comercializadas no municipio de Ribeirao Preto, SR Rev. Soc. Bras. Merl 7i-op. 34, 37–41 (2001).
   Google Scholar
• Takayanagui OM, Lazzarini MPT, Capuano DM et al Prevention of neurocysticercosis: active surveillance of taeniasis among food handlers in Ribeirao Preto-SR Brazil. Ani. Ikuzvpsiquiatn 60\(Suppl. 1), 332–333 (2002).
   Google Scholar